Skip to main content
SpringerLink
Log in

Papillary Thyroid Cancer

Follow-Up

  • Chapter
Thyroid Cancer

Abstract

Effective surveillance for recurrent papillary thyroid cancer begins with an assessment of the likelihood of recurrence or death from disease, based on individual characteristics of the patient and their tumor. This information is used to determine an appropriate level of follow-up, which may vary from as little as an annual neck examination on replacement thyroid hormone therapy for occult lesions to annual or semiannual wholebody scanning (WBS) off thyroid hormone for high-risk patients. Effective follow-up is also contingent upon a current understanding of the strengths and limitations of the tools available for thyroid cancer surveillance. This chapter focuses on the rationale used to determine the method and frequency of follow-up for papillary thyroid cancer patients and gives an overview of the current techniques available to accomplish this objective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid cancer. J Clin Endocrinol Metab 1996; 81: 333–339.

    Article  PubMed  CAS  Google Scholar 

  2. Van Herle AJ, Vassart G, Dumont J. Control of thyroglobulin synthesis and secretion. N Engl J Med Part one: 1979; 301:239–249. Part two: 1979; 301: 307–314.

    Google Scholar 

  3. Izumi M, Larsen PR. Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves’ disease. J Clin Invest 1977; 59: 1105–1112.

    Article  PubMed  CAS  Google Scholar 

  4. Ogawara H, Bilstad JM, Cahnmann HJ. Iodoamino acid distribution in thyroglobulin iodinated in vivo and in vitro. Biochim Biophys Acta 1972; 257: 339–349.

    Article  PubMed  CAS  Google Scholar 

  5. Edelhoch H. The properties of thyroglobulin. VIII. The iodination of thyroglobulin. J Biol Chem 1962; 237: 2778–2787.

    CAS  Google Scholar 

  6. Bertaux F, Noel M, Malthiery Y, Fragu P. Demonstration of a heterogeneous transcription pattern of thyroglobulin mRNA in human thyroid tissue. Biochem Biophys Res Commun 1991; 178: 586–592.

    Article  PubMed  CAS  Google Scholar 

  7. Izumi M, Kubo I, Taura M, Yamashita S, et al. Kinetic study of immunoreative human thyroglobulin. J Clin Endocrinol Metab 1986; 62: 410–412.

    Article  PubMed  CAS  Google Scholar 

  8. Van Herle A.T. Thyroglobulin. In: Werner and Ingbar’s The Thyroid, 6th ed. 1991: 493–505.

    Google Scholar 

  9. Spencer CA, Wang CC. Thyroglobulin measurement: techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995; 24: 841–864.

    PubMed  CAS  Google Scholar 

  10. Volpe R Immunology of human thyroid disease. In: Autoimmune diseases of the endocrine system. Boca Raton, FL: CRC Press, 1990: 76–239.

    Google Scholar 

  11. Saboori AM, Rose NR, Kuppers RC, et al Immunoreactivity of multiple molecular forms of human thyroglobulin. Clin Immunol 1994; 72: 121–128.

    CAS  Google Scholar 

  12. Kiso Y, Furmaniak J, Morteo C, Smith BR. Analysis of carbohydrate residues on human thyroid peroxidase (TPO) and thyroglobulin (Tg) and effects of deglycosylation, reduction and unfolding on autoantibody binding. Autoimmunity 1992; 12: 259–269.

    Article  PubMed  CAS  Google Scholar 

  13. Saboori AM, Caturegli P, Rose NR, et al. Tryptic peptides of human thyroglobulin: II. Immunoreactivity from patients with thyroid diseases. Clin Exp Immunol 1994; 98: 459–463.

    Article  PubMed  CAS  Google Scholar 

  14. Caturegli P, Mariotti S, Kuppers RC, et al. Epitopes on thyroglobulin: a study of patients with thyroid disease. Autoimmunity 1994; 18: 41–49.

    Article  PubMed  CAS  Google Scholar 

  15. Piechaczyk M, Bouanani M, Salhi SL, et al. Antigenic domains on the human thyroglobulin molecule recognized by autoantibodies in patients’ sera and by natural autoantibodies isolated from the sera of healthy subjects. Clin Immunol Immunopathol 1987; 45: 114–121.

    Article  PubMed  CAS  Google Scholar 

  16. Prentice L, Kiso Y, Fukuma N, et al. Monoclonal thyroglobulin autoantibodies: variable region analysis and epitope recognition. J Clin Endocrinol Metab 1995; 80: 977–986.

    Article  PubMed  CAS  Google Scholar 

  17. Phillips D, McLachlan S, Stephenson A, et al. Autosomal dominant transmission of autoantibodies to thyroglobulin and thyroid peroxidase. J Clin Endocrinol Metab 1990; 70: 742–746.

    Article  PubMed  CAS  Google Scholar 

  18. Torrens JI, Burch HB. Clinical application of serum thyroglobulin testing. Endocrinologist 1996; 6: 125–144.

    Article  Google Scholar 

  19. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42: 164–173.

    PubMed  CAS  Google Scholar 

  20. Feldt-Rasmussen U, Rasmussen K. Serum thyroglobulin (TG) in presence of thyroglobulin autoantibodies (TgAb): clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. J Endocrinol Invest 1985; 8: 571–576.

    PubMed  CAS  Google Scholar 

  21. Schneider AB, Pervos R. Radioimmunoassay of human thyroglobulin: effects of antithyroglobulin autoantibodies. J Clin Endocrinol Metab 1978; 47: 126–137.

    Article  PubMed  CAS  Google Scholar 

  22. Ross DS. Long-term management of differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 719–739.

    PubMed  CAS  Google Scholar 

  23. Cole TG, Johnson D, Eveland BJ, Nahm MH. Cost effective method for detection of “hook effect” in tumor marker immunometric assays. Clin Chem 1993; 39: 695–696.

    PubMed  CAS  Google Scholar 

  24. Aiello DP, Manni A. Thyroglobulin measurement vs iodine 131 total-body scan for follow up of well-differentiated thyroid cancer. Arch Intern Med 1990; 150: 437–439.

    Article  PubMed  CAS  Google Scholar 

  25. Lindegaard MW, Paus E. Thyroglobulin in patients with differentiated thyroid carcinoma. Scand J Clin Lab Invest Suppl 1991; 206: 79–84.

    Article  PubMed  CAS  Google Scholar 

  26. Dralle H, Schwarzrock R, Lang W, et al. Comparison of histology and immunohistochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas. Acta Endocrinol (Copenh) 1985; 108: 504–510.

    CAS  Google Scholar 

  27. Schlumberger M, Fragu P, Parmentier C, Tubiana M. Thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinomas: comparison of its value in patients with or without normal residual tissue. Acta Endocrinol (Copenh) 1981; 98: 215–221.

    CAS  Google Scholar 

  28. Ashcraft MW, Van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981; 71: 806–814.

    Article  PubMed  CAS  Google Scholar 

  29. Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98–105.

    Article  PubMed  CAS  Google Scholar 

  30. Harvey RD, Matheson NA, Grabowski PS, Rodger AB. Measurement of serum thyroglobulin is of value in detecting tumor recurrence following treatment of differentiated thyroid carcinoma by lobectomy. Br J Surg 1990; 77: 324–326.

    Article  PubMed  CAS  Google Scholar 

  31. Girelli ME, Busnardo B, Amerio R, et al. Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone withdrawal and total body scan: results in 291 patients with thyroid cancer. Eur J Nucl Med 1986; 11: 333–335.

    Article  PubMed  CAS  Google Scholar 

  32. Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol 1987; 27: 115–120.

    Article  CAS  Google Scholar 

  33. Black EG, Sheppard MC. Serum thyroglobulin measurements in thyroid cancer: evaluation of “false” positive results. Clin Endocrinol 1991; 35: 519–520.

    Article  CAS  Google Scholar 

  34. Baskin HJ. Effect of postoperative 131I treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer. Thyroid 1994; 4: 239–242.

    Article  PubMed  CAS  Google Scholar 

  35. Mazzaferri EL. Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? [Editorial]. J Clin Endocrinol Metab 1995; 80: 1485–1487.

    Article  PubMed  CAS  Google Scholar 

  36. Black EG, Gimlette TMD, Maisey MN, et al. Serum thyroglobulin in thyroid cancer. Lancet 1981; 1: 443–445.

    Article  Google Scholar 

  37. Ashcraft MW, Van Herle Ai. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981; 71: 806–814.

    Article  PubMed  CAS  Google Scholar 

  38. Robbins J, Merino MJ, Boice JD, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991; 115: 133–147.

    PubMed  CAS  Google Scholar 

  39. Schneider AB, Line B, Goldman JM, Robbins J. Sequential serum thyroglobulin determinations, 131I scans, and I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 1981; 53: 1199–1206.

    Article  PubMed  CAS  Google Scholar 

  40. Hüffner M, Stumpf HP, Grussendorf M, et al. A comparison of the effectiveness of 131I whole body scans and plasma Tg determinations in the diagnosis of metastatic differentiated carcinoma of the thyroid: a retrospective study. Acta Endocrinol (Copenh) 1984; 104: 327–332.

    Google Scholar 

  41. Barsano CP, Skosey C, DeGroot LJ, Refetoff S. Serum thyroglobulin in the management of patients with thyroid cancer. Arch Intern Med 1982; 142: 763–767.

    Article  PubMed  CAS  Google Scholar 

  42. Ramanna L, Waxman AD, Brachman MB, et al. Correlation of thyroglobulin measurements and radioiodine scans in the follow-up of patients with differentiated thyroid cancer. Cancer 1985; 55: 1525–1529.

    Article  PubMed  CAS  Google Scholar 

  43. Ericsson UB, Tegler L, Lennquist S, et al. Serum thyroglobulin in differentiated thyroid carcinoma. Acta Chir Scand 1984; 150: 367–375.

    PubMed  CAS  Google Scholar 

  44. Schlumberger M, Parmentier C, de Verthaire F, Tubiana M. 131I and external radiation in the treatment of local and metastatic thyroid cancer. In Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. Raven Press, 1990, pp. 537–552.

    Google Scholar 

  45. Lubin E, Mechlis-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35: 257–262.

    PubMed  CAS  Google Scholar 

  46. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188–196.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Henry B. Burch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Washington Hospital Center, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

  2. Uniformed Services University of Health Sciences, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

  3. George Washington University of Schools of Medicine, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Burch, H.B. (2000). Papillary Thyroid Cancer. In: Wartofsky, L. (eds) Thyroid Cancer. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-199-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-199-2_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6845-9

  • Online ISBN: 978-1-59259-199-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation